BiotechTube

micafungin + Micafungin + Caspofungin

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Candidemia

Conditions

Candidemia

Trial Timeline

Dec 1, 2008 → May 1, 2010

NCT ID
NCT00839540

About micafungin + Micafungin + Caspofungin

micafungin + Micafungin + Caspofungin is a approved stage product being developed by Astellas Pharma for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00839540. Target conditions include Candidemia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00839540ApprovedCompleted

Competing Products

9 competing products in Candidemia

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaApproved
85
AmBisomeGilead SciencesApproved
84
Anidulafungin/FluconazolePfizerPhase 3
76
Anidulafungin + VoriconazolePfizerApproved
84
Anidulafungin + FluconazolePfizerPhase 3
76
AnidulafunginPfizerPhase 3
76
Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
72
APX001Basilea PharmaceuticaPhase 2
47
APX001Basilea PharmaceuticaPhase 2
47

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85